Lang Wang1, 2, Qian Zhou1, 2, Xiaoxi Tan1, 2, Ziyuan Wu1, 2, Chan Fu1, 2, Yun Liu1, 2, Bo Zhang1, 3, *
1Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital, Central South University, Changsha, PR China - 2Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, PR China - 3Department of Health Management Center, The Second Xiangya Hospital, Central South University, Changsha, PR China
Objective: About 150,000 people die from bladder cancer every year, making it the ninth most common cancer in the world. It is characterized by local invasion, easy metastasis and a high recurrence rate and is a severe threat to human health. This study was designed to investigate the treatment of advanced bladder cancer with DC-CIK cell therapy, including treatment outcomes and satisfaction and compliance with nursing care in patients undergoing the treatment.
Methods: In this study, 20 patients with advanced bladder cancer were treated with DC-CIK cell therapy plus chemotherapy or chemotherapy alone. Treatment outcomes were assessed after 1, 2 and 3 years. Subsequently, we performed a retrospective chart analysis of changes in T cell subsets, treatment efficacy, overall survival rate, disease-free survival rate, patient compliance with treatment and satisfaction with nursing care.
Results: Autologous DC-CIK cells plus chemotherapy were significantly more effective in the treatment of advanced bladder cancer than chemotherapy alone. The disease control rate was 57.5% in the experimental group and 85% in the control group.
Conclusion: Careful nursing and observation and timely treatment of adverse reactions after treatment can significantly improve patients' symptoms as well as their and their family's satisfaction.
Autologous DC-CIK cells, advanced bladder cancer, nursing effect, cell therapy.